During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS). MyoIns has been shown to affect different pathways at both ovarian and non-ovarian level. On the contrary, D-chiroIns alone is unable to exert significant improvements in the ovarian cell functions, as its beneficial effects are mainly limited to the non-ovarian tissue in which it may significantly inhibit the negative cellular consequences of hyperinsulinemia. However, both Ins isomers can be positively associated in the management of PCOS patients in a ratio corresponding to their physiological plasma ratio (40:1). This appears to exert a synergistic effect according to a multi-targeted design. In this respect, new fundamental insights into the biological mechanisms displayed by Ins, as well as clinical trials based on the myoIns + D-chiroIns formulations, have already provided encouraging results.

Physiological role and clinical utility of inositols in polycystic ovary syndrome / Bevilacqua, Arturo; Bizzarri, Mariano. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY. - ISSN 1521-6934. - STAMPA. - ---:---(2016), pp. 1-11. [10.1016/j.bpobgyn.2016.03.007]

Physiological role and clinical utility of inositols in polycystic ovary syndrome

BEVILACQUA, Arturo;BIZZARRI, Mariano
2016

Abstract

During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS). MyoIns has been shown to affect different pathways at both ovarian and non-ovarian level. On the contrary, D-chiroIns alone is unable to exert significant improvements in the ovarian cell functions, as its beneficial effects are mainly limited to the non-ovarian tissue in which it may significantly inhibit the negative cellular consequences of hyperinsulinemia. However, both Ins isomers can be positively associated in the management of PCOS patients in a ratio corresponding to their physiological plasma ratio (40:1). This appears to exert a synergistic effect according to a multi-targeted design. In this respect, new fundamental insights into the biological mechanisms displayed by Ins, as well as clinical trials based on the myoIns + D-chiroIns formulations, have already provided encouraging results.
2016
D-chiroinositol; inositol; insulin; myoinositol; polycystic ovary syndrome
01 Pubblicazione su rivista::01a Articolo in rivista
Physiological role and clinical utility of inositols in polycystic ovary syndrome / Bevilacqua, Arturo; Bizzarri, Mariano. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY. - ISSN 1521-6934. - STAMPA. - ---:---(2016), pp. 1-11. [10.1016/j.bpobgyn.2016.03.007]
File allegati a questo prodotto
File Dimensione Formato  
Bevilacqua_Physiological-role_2016.pdf

solo gestori archivio

Note: Articolo principale
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 600.75 kB
Formato Adobe PDF
600.75 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/865986
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 19
social impact